173 related articles for article (PubMed ID: 31991138)
1. In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the β-arrestin2 recruitment assay: No two ligands have the same profile.
Kuo A; Magiera J; Rethwan N; Andersson Å; Leen Lam A; Wyse B; Meutermans W; Lewis R; Smith M
Eur J Pharmacol; 2020 Apr; 872():172947. PubMed ID: 31991138
[TBL] [Abstract][Full Text] [Related]
2. CYX-5, a G-protein biassed MOP receptor agonist, DOP receptor antagonist and KOP receptor agonist, evokes constipation but not respiratory depression relative to morphine in rats.
Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
Pharmacol Rep; 2023 Jun; 75(3):634-646. PubMed ID: 36637684
[TBL] [Abstract][Full Text] [Related]
3. In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.
Kuo A; Wyse BD; Meutermans W; Smith MT
Br J Pharmacol; 2015 Jan; 172(2):532-48. PubMed ID: 24641546
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Biological Evaluation of Fentanyl Analogues Modified at Phenyl Groups with Alkyls.
Qin Y; Ni L; Shi J; Zhu Z; Shi S; Lam AL; Magiera J; Sekar S; Kuo A; Smith MT; Li T
ACS Chem Neurosci; 2019 Jan; 10(1):201-208. PubMed ID: 30179508
[TBL] [Abstract][Full Text] [Related]
5. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
[TBL] [Abstract][Full Text] [Related]
6. Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity.
Cai J; Song B; Cai Y; Ma Y; Lam AL; Magiera J; Sekar S; Wyse BD; Ambo A; Sasaki Y; Lazarus LH; Smith MT; Li T
Bioorg Med Chem; 2014 Apr; 22(7):2208-19. PubMed ID: 24613457
[TBL] [Abstract][Full Text] [Related]
7. Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain.
Rutten K; Schröder W; Christoph T; Koch T; Tzschentke TM
Eur J Pharmacol; 2018 May; 827():41-48. PubMed ID: 29524385
[TBL] [Abstract][Full Text] [Related]
8. Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.
Bird MF; Vardanyan RS; Hruby VJ; Calò G; Guerrini R; Salvadori S; Trapella C; McDonald J; Rowbotham DJ; Lambert DG
Br J Anaesth; 2015 Apr; 114(4):646-56. PubMed ID: 25680364
[TBL] [Abstract][Full Text] [Related]
9. The μ-opioid receptor-mediated G
Xia J; Li X; Zhu H; Zhou X; Chen J; Li Q; Li S; Chu H; Dong M
Eur J Pharmacol; 2024 Mar; 966():176333. PubMed ID: 38278466
[TBL] [Abstract][Full Text] [Related]
10. Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity.
Kumar V; Ridzwan IE; Grivas K; Lewis JW; Clark MJ; Meurice C; Jimenez-Gomez C; Pogozheva I; Mosberg H; Traynor JR; Husbands SM
J Med Chem; 2014 May; 57(10):4049-57. PubMed ID: 24761755
[TBL] [Abstract][Full Text] [Related]
11. Opioid Receptors in Immune and Glial Cells-Implications for Pain Control.
Machelska H; Celik MÖ
Front Immunol; 2020; 11():300. PubMed ID: 32194554
[TBL] [Abstract][Full Text] [Related]
12. Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects.
Smith MT; Kong D; Kuo A; Imam MZ; Williams CM
J Med Chem; 2023 Mar; 66(6):3746-3784. PubMed ID: 36856340
[TBL] [Abstract][Full Text] [Related]
13. Opioid receptors mRNAs expression and opioids agonist-dependent G-protein activation in the rat brain following neuropathy.
Llorca-Torralba M; Pilar-Cuéllar F; da Silva Borges G; Mico JA; Berrocoso E
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Apr; 99():109857. PubMed ID: 31904442
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of Dynorphin fragments at the κ, μ and δ opioid receptor in transfected HEK cells and in an animal model of unilateral peripheral inflammation.
Morgan M; Heffernan A; Benhabib F; Wagner S; Hewavitharana AK; Shaw PN; Cabot PJ
Peptides; 2017 Mar; 89():9-16. PubMed ID: 28049031
[TBL] [Abstract][Full Text] [Related]
15. The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.
Atigari DV; Paton KF; Uprety R; Váradi A; Alder AF; Scouller B; Miller JH; Majumdar S; Kivell BM
Neuropharmacology; 2021 Mar; 185():108445. PubMed ID: 33383089
[TBL] [Abstract][Full Text] [Related]
16. Hot topics in opioid pharmacology: mixed and biased opioids.
Azzam AAH; McDonald J; Lambert DG
Br J Anaesth; 2019 Jun; 122(6):e136-e145. PubMed ID: 31010646
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the Activity of Spinal and Thalamic Opioid Systems in a Mice Neuropathic Pain Model.
Rojewska E; Wawrzczak-Bargiela A; Szucs E; Benyhe S; Starnowska J; Mika J; Przewlocki R; Przewlocka B
Neuroscience; 2018 Oct; 390():293-302. PubMed ID: 30176322
[TBL] [Abstract][Full Text] [Related]
18. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2015 Jan; 172(2):375-87. PubMed ID: 24571499
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.
Rutten K; Tzschentke TM; Koch T; Schiene K; Christoph T
Eur J Pharmacol; 2014 Oct; 741():264-71. PubMed ID: 25169429
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.
Dietis N; Guerrini R; Calo G; Salvadori S; Rowbotham DJ; Lambert DG
Br J Anaesth; 2009 Jul; 103(1):38-49. PubMed ID: 19474215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
